Background: Because of the physiological decline and the diversity of preferences, treating older patients with cancer is challenging. Given the insufficient evidence applicable to treating cancer in older patients, some clinical guidance is necessary. This study provides a description of current treatment practices in Japan, which may shed light on possible treatment options. Methods: Using data from the national database of hospital-based cancer registries, we described the first-course treatment of nine common cancers in patients who received care in Designated Cancer Care Hospitals between 2012 and 2015. We compared the patterns of first-course cancer treatment between younger and older patients. Results: In total, 1 383 066 cases were analysed. The proportion of patients aged >75 years receiving first-course treatment has gradually increased since 2012 (range: 0.9% point increase for colorectal cancer to 2.7% point increase for stomach cancer). A higher proportion of patients aged ≥85 years, compared with younger patients, did not receive any treatment. Conclusions: Based on this cancer registry-based analysis, older patients-in particular those ≥85 years old at diagnosis and with advanced stage cancer-are less likely to receive anti-cancer treatment than younger patents are. Further research is warranted to identify patient characteristics that predict which older patients are most likely to benefit from active treatment.
Introduction
While societal ageing is a global trend, Japan has the highest rate of ageing in the world; the proportion of individuals aged ≥65 years in the total Japanese population reached 27.3% in 2016 (1) . Age is associated with a progressive decline in the functional reserve of multiple organ systems and an increased incidence of chronic disease such as cancer (2) . Thus, while managing such patients is a challenge, clinicians treat substantial numbers of older patients with cancer. Despite the fact that older patients account for a substantial proportion of those with cancer, they are disproportionately underrepresented in the clinical trials that produce definitive evidence to guide clinical care (3) .
The National Comprehensive Cancer Network (NCCN) in the US has published guidelines for older adult oncology; these guidelines recommend undertaking an assessment of whether the expected benefits of treatment outweigh the risks thereof in a population with decreased life expectancy and decreased tolerance to stress (4) . Age should not be the sole determinant for making treatment decisions. When deciding on the most appropriate cancer treatment for older patients, the biologic characteristics of the specific cancer, its responsiveness to therapy, and the patient's tolerability of anti-cancer therapy should be considered. In addition, the preferences of the patient and his/her family should be taken into account. A previous survey of older patients with serious illnesses reported that the burden of treatment, and its outcomes, and the likelihood of a favourable outcome all influence treatment preference (5) . Moreover, age has been found to be inversely related to receiving chemotherapy in cases of metastatic lung cancer and of undergoing aggressive surgery in cases of brain, lung or colorectal cancer (3, (6) (7) (8) (9) .
In Japan, the National Cancer Control Plan of 2017 states that clinical practice guidelines to support decision-making regarding treatment plans for older patients with cancer should be developed (10) . However, to our knowledge, there are few local data outlining the patterns of treating cancer in older patients. Cancer registries provide the unique opportunity to evaluate the treatments given in routine practice and to assess the influence of these treatments on progress (11) . As the division responsible for the national operation of hospital-based cancer registries (HBCR) in the nationwide designated cancer care hospitals (DCCHs), we added to the official annual report of HBCR in 2015 a chapter that described the distribution of cancer stage and the patterns of first-course cancer treatment by different age groups (12) . Here, we present the results and further discuss cancer treatment provided to older patients with nine common cancers (stomach, colorectal, small cell lung cancer [SCLC] , non-small cell lung cancer [NSCLC] , breast, pancreas, cervix, prostate and bladder).
Methods

Data source
We abstracted data from the Cancer Registry Report of the Nationwide DCCHs in 2015 (8) ; this report compiles the HBCR data from the DCCHs. The Japanese Ministry of Health, Labour and Welfare designates cancer hospitals in order to provide a high quality of cancer care. In 2015, there were 427 DCCHs in Japan. The National Cancer Center has published an annual Cancer Registry Report since 2007, when the data of patients diagnosed with cancer started being routinely collected. The HBCR of the DCCHs cover~67% of patients newly diagnosed with cancer in Japan (13) . In addition to the routine statistical report, the 2015 report provided a section that compared the current status of cancer diagnosis and treatment between older and younger patients.
In the HBCR, trained cancer registrars at a hospital registered each cancer case based on standardized rules and criteria. The HBCR includes information on demographic characteristics (sex and birthdate), tumour characteristics (topography, morphology and the 7th International Union Against Cancer TNM Classification of Malignant Tumours stage) and first-course treatment (surgery, radiation and chemotherapy). In the HBCR, first-course treatment is defined as a planned treatment that either affects cancer prognosis (i.e., stops cancer progression, removes the cancer or results in cancer regression) or aims to relieve symptoms caused by tumours per se. Any additional treatment planned after the start of cancer therapy was not included. Patients treated with chemotherapy or immunotherapy were categorized as patients receiving pharmacotherapy. The first-course treatment provided at the registering facility is recorded in the HBCR.
Identification of cancer cases
We abstracted the data of the following cancer cases: (i) diagnosed with cancer between 2012 and 2015 and received first-course cancer treatment at a DCCH; (ii) registered site of the cancer was the stomach (C16), colorectum (C18-20), lung (C33-34), breast (C50), pancreas (C25), cervix (C53), prostate (C61) or bladder (C67); and (iii) with the following International Classification of Diseases for  Oncology 3rd edition histology codes: 8051-8084, 8090-8110,  8120-8131, 8140-8149, 8160-8162, 8190-8221, 8260-8337, 8350-8551, 8570-8576, 8940-8941, 8030-8046, 8150-8157, 8170-8180,  8230-8231, 8246-8247, 8250-8255, 8340-8347, 8560-8562, 8580-8671, 8010-8015, 8020-8022, 8050 , and 8000-8005. Cases with histology codes 8240-8245, 8248 or 8249 with a site code of C33-34 (lung) or C25 (pancreas) were also included, but transitional cell papilloma and carcinoma (histology codes 8120-8131) for prostate cancer (C61) were excluded. We compared the patterns of firstcourse treatment stratified by age in years, in the following groups: 40-64 years, 65-74 years, 75-84 years and ≥85 years. Patients with Tis cancers (carcinoma in situ) were also included in this study.
Summary cancer staging
In the HBCR, both the clinical and pathological UICC TNM classifications are registered; however, the pathological stage is not recorded for patients who receive chemotherapy or radiation therapy before undergoing surgical resection. In this study, we used a summary stage combining the clinical and pathological stages; the pathological stage was used for patients who had this information available whereas the clinical stage was used for those who did not. When we analysed distributions of stage using clinical stage, the percentage of unknown stage was lager, in particular colorectal cancer (0.5-47% in summary stage; 15.2-20.3% in clinical stage) and bladder cancers (1.6-5.1% in summary stage; 9.9-14.3% in clinical stage). The treatment patterns at each cancer and stage are almost similar. Therefore, we used the summary stage in this study.
Data analysis
First, we described the distribution of age and summary stage (reflecting prognosis) of each cancer. Then, we examined the patterns of first-course treatment received stratified by summary stage and age.
Ethical considerations
All data included in this paper were publicly available from the Cancer Information Service of the National Cancer Centre as part of the Report of HBCR of 2015 (12) . According to the research ethics guidelines in Japan, studies that use only publicly available data are exempt from requiring ethical review.
Results
In total, 1 383 066 cases were analysed, comprising cases of cancer in the following sites: stomach (n = 258 071), colorectum (n = 316 892), lung (SCLC, n = 20 453 and NSCLC, n = 218 537), breast (n = 192 766), pancreas (n = 68 027), cervix (n = 82 748), prostate (n = 155 687) and bladder (n = 69 885). Table 1 shows the age distribution of each cancer type. The proportion of patients in the <65-year-old age group decreased from 2012 to 2015 (ranging from a 0.8% point decrease for cervical cancer to a 5.9% point decrease for stomach cancer). For cervical cancer, the proportion of patients <40 years old decreased from 43.3% in 2012 to 41.2% in 2015. On the other hand, the proportion of patients in the >75-year-old group gradually increased (0.9% point increase for colorectal cancer and 2.7% point increase for stomach cancer).
No major differences in summary stage distribution were observed among the age groups and cancer sites during study period ( Table 2 ). The proportion of patients with summary Stage 0 or I cancer in the ≥85-year-old group was relatively lower than in the other age groups, except for SCLC and pancreas cancer, for which the distribution of summary stage by age was similar. The proportion of Stage IV cancers in the ≥85-year-old group was similar to those of the other age groups, except for cancers of the lung (NSCLC), cervix and prostate, where the proportion of Stage IV cancers in the ≥85-year-old group was slightly higher than in the other age groups. The proportion of summary Stage IV pancreas and bladder cancers was slightly higher in the younger (≤64-yearold) than in the oldest (≥85-year-old) age group. Table 3 shows the patterns of first-course cancer treatment provided, stratified by cancer type, stage and age. The patterns of treatment for each cancer and stage differed between younger and older patients. Except for those with prostate cancer, the proportion of cases who did not receive any treatment was higher in the ≥85-yearold group, in particular among patients with more advanced stages, than in the younger age groups. In the ≥85-year-old group, the proportion of cases with Stage IV breast cancer who did not receive any treatment was 21.6%, the corresponding proportions were 60.6%, 58.3% and 51.7% for Stage IV cancers of the pancreas, lung (NSCLC), and stomach, respectively. The older patient groups received combination therapy less frequently than the younger patient groups did.
For patients with Stage III stomach or colorectal cancer, >50% of cases in the 40-64-year-old groups received combination therapy comprising surgery and pharmacotherapy (79.0% for stomach and 73.9% for colorectal cancer), while <8% of corresponding cases in the ≥85-year-old group received such therapy (7.6% for stomach and 6.3% for colorectal cancer); the ≥85-year-old group more frequently received surgery alone (64.6% for stomach and 80.2% for colorectal cancer). For patients with Stage III SCLC and NSCLC, a substantial proportion of 40-64-year-olds received combination therapy comprising radiation therapy and pharmacotherapy (65.9% for SCLC, 34.6% for NSCLC); <10% of patients in the ≥85-yearold group received such therapy (9.4% for SCLC, 2.3% for NSCLC).
For breast cancer, the treatments received by the 75-84-year-old and ≥85-year-old groups were similar to those received by the younger age groups, except that a slightly lower proportion of patients in the ≥85-year-old group received combination therapy. Among patients ≤84 years old with Stage II or III breast cancer, no major age-related difference was observed in terms of the proportion of patients who received combination surgery and pharmacotherapy (ranges: 53.5-56.2% for Stage II and 40.8-44.1% for Stage III). More than 50% of patients in all age groups with Stage IV breast cancer received pharmacotherapy.
For Stage I colorectal cancer, the treatment patterns were similar in the age groups up to 85 years, but 15.9% of patients aged ≥85 years received no treatment. For prostate cancer, 13.8-18.5% of patients with Stage I disease received no treatment. A greater proportion of younger patients with Stage II or III prostate cancer underwent surgery, while those aged >75 years tended to receive pharmacotherapy and surgical castration. The pattern of treatment for cases with Stage IV prostate cancer was similar among the age groups. For patients with Stage I NSCLC, a greater proportion of younger patients received surgery alone, while a greater proportion of patients aged ≥85 years received radiation therapy alone (34.9%) or surgery alone (34.8%).
Discussion
This study illustrates that the number of older patients attended to at the DCCHs with one of the nine cancers evaluated has gradually been increasing. The HBCR data show that the patterns of treatment for each cancer and stage differ between younger and older patients, except for breast cancer and Stage I colorectal cancer (12) . The proportion of patients in the ≥85-year-old group who did not receive any treatment was higher than was observed in the younger patient groups. Tumour biology, treatment tolerability, and the effect of comorbid conditions all affect decisions around the choice of cancer treatment. For example, the present study found that among patients with cancer of the pancreas, those aged ≥85 years were less likely than younger patients to be treated. A similar trend was reported in a previous study from the US (14) .
Adjuvant therapy after surgery is provided to prevent cancer recurrence (15) . Our data indicate that a lower proportion of older (17, 18) . Unfortunately, because no data on comorbid conditions were available in the previous study and our study, the reasons why subsets of patients did or did not receive adjuvant chemotherapy are indeterminable. One possible reason is that older patients may be at increased risk of haematological toxicity (4). Another possible reason is patient and family preferences. A previous survey of older patients with seriously illnesses reported that the burden of treatment, its outcomes, and the likelihood of a favourable outcome all influence treatment preference (5). Akishita et al. conducted the survey to ask both healthcare providers who care older patients and their patients/families in Japan about the relative priorities of 12 healthcare measures (i.e., improvement of quality of life, patient satisfaction with care, improvement of physical function) (19) . They reported that both healthcare providers and older patients/their families ranked 'mortality reduction' as being the least important factor in deciding on a treatment strategy (19) , suggesting that the treatment preferences of patients and their families also impact the decision not to receive adjuvant therapy. Previous studies have reported that, compared with younger women, women older than 75 years are usually managed with less aggressive treatment and have higher mortality rates from earlystage breast cancer (11, 20, 21) . Our data indicate that breast cancer patients aged 75-84 years received treatment that was not different from that received by younger patients, while patients older than 85 years seemed to be managed with slightly less aggressive treatment. Breast cancer in older women is associated with more favourable tumour biology due to the high prevalence of hormone receptor- Continued positive, HER2-negative, slowly proliferating tumours (22, 23) ; this information was not available in our data. However, it is important to note that tumour biology in older patients can affect treatment choice. In the present study, the patterns of treating Stage I colorectal cancer were quite similar among all age groups. In a study that evaluated agerelated surgical risk and outcomes in patients with colorectal cancer, the long-term outcomes after surgery were found to be more dependent on disease stage and the type of adjuvant or palliative treatment received than they were on age (24) . Therefore, the NCCN guidelines recommend that age alone should not be a contraindication for curative surgery in older patients with early-stage, resectable colorectal cancer (4, 24) .
In the present study, 13.8-18.5% of patients with Stage I prostate cancer did not receive any treatment. A study from the US reported that the most common treatment provided for patients aged >65 years with prostate cancer is radiation therapy (57.9%), followed by radical prostatectomy (19.1%) and watchful waiting or active surveillance (9.6%) (25) . In their study, the researchers imputed the treatment category 'watchful waiting' based on the lack of any recorded treatment over a 2-year period. Our corresponding treatment category was based on a much shorter period of several months. Therefore, our results should be interpreted with caution.
The most common treatment choices for Stage I or II NSCLC and prostate cancer differ according to age. For early-stage NSCLC patients, surgical resection and mediastinal lymph node dissection is recommended as the standard treatment (26) . Our data show that NSCLC patients ≥85 years old were less likely to receive surgery and more likely to receive radiation therapy. Lung cancer guidelines recommended radiotherapy for medically unresectable lung cancer patients (26) . In general, elderly patients tend to have poor respiratory and cardiovascular functions. These patients' conditions can affect treatment choices for the elderly. The International Society of Geriatric Oncology developed treatment guidelines for men with prostate cancer aged >70 years (27, 28) . They suggest that the heterogeneity of the elderly population necessitates a multidimensional assessment to maximize the benefit of medical and/or surgical treatment options (28) .
The present study has several limitations due to the availability of data in the HBCR. First, no detailed information regarding an individual patient's clinical condition is available in the registry. Such information, including functional status and comorbidities, are important in making treatment decisions for older patients with cancer (29, 30) . Future studies should assess how treatments decisions are made and what influence comorbidities or poor performance status exerts. Second, the data contained details of only the first-course treatment provided at the registering facility; data regarding treatment provided at other hospitals or additional treatment not initially planned but provided in response to disease progression are not captured. Hence, referral patterns and disease progression may have influenced the results (31) . Finally, the report only contains data from the DCCHs that play a central role in cancer care in the community or region and are expected to provide high-quality anti-cancer care for patients. Other hospitals may treat older patients differently and perhaps are more likely to refrain from providing active treatment to older patients. Although the HBCR covers two-thirds of all cancer patients in Japan, additional data from other hospitals may be required to gain a more accurate national profile of cancer care provided to older patients.
Conclusion
Cancer registries provide the unique opportunity to evaluate treatments given in routine practice and to assess the influence of treatment on progress (11) . This study illustrates that the number of older patients attended to at the DCCHs with one of the nine cancers evaluated has gradually increased, and that the patterns of treatment differ between younger and older patients. Heterogeneity among older patients necessitates a multidimensional assessment to maximize the benefit of medical and/or surgical management options (28) . In addition, the patients' treatment preferences, and those of their family members, also influence treatment planning. Further research should focus on identifying tumour and patient characteristics that can assist in targeting treatments toward those older patients who are most likely to benefit therefrom.
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